bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.07.09.663936

Borzoi-informed fine mapping improves causal variant prioritization in complex trait GWAS

Abstract

1Genome-wide association studies (GWAS) have identified thousands of trait-associated loci. Prioritizing causal variants within these loci is critical for characterizing trait biology. Statistical fine mapping identifies causal variants at trait-associated loci, but linkage disequilibrium (LD) and limited GWAS sample sizes prevent the resolution of many associations. Functionally informed approaches augment fine mapping by estimating variant prior causal probabilities based on overlap with trait-relevant functional annotations. However, functional enrichment provides only an indirect proxy for variant functional impact. Sequence-to-function models directly estimate variant effects on molecular phenotypes from underlying sequence context. Borzoi is a long-context model that predicts sequence determinants of transcription, splicing, and polyadenylation across diverse tissues and cell types. Here we present Sniff, a Borzoi-informed fine-mapping approach that integrates broad genomic functional annotations with Borzoi-predicted variant effects via PolyFun to estimate variant prior causal probabilities. Applied to 15 UK Biobank traits, Sniff identifies 9.45% additional fine-mapped variants compared to PolyFun-Baseline at posterior inclusion probability (PIP) > 0.8. Sniff-prioritized variants exhibit allele-specific activity in reporter assays and are predicted to have tissue-specific activity in trait-relevant tissues. For most traits, genes nominated by Sniff receive higher scores from the orthogonal gene prioritization method PoPS compared to genes nominated using functional annotations alone. Because differentially prioritized variants are driven by Borzoi predictions, we leverage attribution techniques to characterize sequence features underlying fine mapping and generate mechanistic hypotheses for GWAS associations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Srivastava, D., Korsakova, A., Wang, Q., Ruiz, L., Yuan, H., Kelley, D. R.. 2025-07-14. Borzoi-informed fine mapping improves causal variant prioritization in complex trait GWAS. https://doi.org/10.1101/2025.07.09.663936

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗